Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach
Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measu...
Gespeichert in:
Veröffentlicht in: | Annals of hematology 2006-11, Vol.85 (11), p.795-805 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 805 |
---|---|
container_issue | 11 |
container_start_page | 795 |
container_title | Annals of hematology |
container_volume | 85 |
creator | Passam, Freda Tachynopoulou, Varvara Skoumi, Dimitra Tsompanakou, Aliki Stavropoulos-Giokas, Aikaterini Vadikolia, Chrysanthi Anagnostopoulos, Achilles Paterakis, Georgios |
description | Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measurement in CLL samples. Samples from 61 CLL patients and 44 normal subjects were analyzed using a commercial ZAP-70 monoclonal antibody (1E7.2 clone) conjugated with phycoerythrin (PE) and Alexa 488 fluorochromes. Modifications of the published methods led to the structure of a simplified in-house method of ZAP-70 measurement. A three-color approach was used with CD19, CD3 gating comparing with the isotype control provided by the same manufacturer. The cutoff levels for ZAP-70 positivity were defined from a receiver operator characteristic curve in relation to the IgV(H) mutational status and from the ln normalized mean value +2 SD of normal controls. Using the 20% cutoff value for ZAP-70 positivity in CLL patients defined by the literature, ZAP-PE had a sensitivity of 55% and a specificity of 98% in predicting the IgV(H) mutational status, whereas the corresponding values for ZAP-Alexa were 55% and 84%, respectively. Using the 7% cutoff value for CD38 positivity, the sensitivity was 55%, whereas the specificity was 76%. ZAP-70-positive patients showed a shorter time to disease progression in comparison with ZAP-70-negative patients (p < 0.001). In conclusion, the 100% specific prediction of mutational status is accompanied by reduced sensitivity, thus limiting ZAP-70's applicability either as a single marker or combined with CD38 for the assessment of the mutational status of CLL. |
doi_str_mv | 10.1007/s00277-006-0159-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68846812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68846812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-1ad7d885d0926ca3136c614db1a1e9f0e2136a1dab695f435a2a85fbd6e150fa3</originalsourceid><addsrcrecordid>eNpdkUGL1TAUhYMoznP0B7iR4MJdNDdp09TdY3BUGNCFbtyENL2dZkybZ9Ii_Tn-U1PeA8FsEs4995zAR8hL4G-B8-Zd5lw0DeNcMQ51y6pH5ACVFIzXunpMDryVLavLuSLPcn7gHISuxFNyBUo3IHV7IH9u0Wbf-eCXjcaB2pnuQtioPZ2Cd7YLSCdcxtjv4x_Hr6zhRbB5TTjhvFA_UzemOHtHwzadxui2ZX_j-hMnb_f5MiJNcV38jHQI8TctllhC00YzLkW-f0-Pl5YY4n2pDXt_itaNz8mTwYaMLy73Nfl---HbzSd29-Xj55vjHXOVgIWB7Zte67rnrVDOSpDKKaj6DixgO3AURbHQ20619VDJ2gqr66HrFULNByuvyZtzbqn9tWJezOSzwxDsjHHNRmldKQ2iGF__Z3yIa5rL34wC2dYcWllMcDa5FHNOOJhT8pNNmwFudnjmDM8UeGaHZ6qy8-oSvHYT9v82LrTkX5Kbl9M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>613950193</pqid></control><display><type>article</type><title>Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Passam, Freda ; Tachynopoulou, Varvara ; Skoumi, Dimitra ; Tsompanakou, Aliki ; Stavropoulos-Giokas, Aikaterini ; Vadikolia, Chrysanthi ; Anagnostopoulos, Achilles ; Paterakis, Georgios</creator><creatorcontrib>Passam, Freda ; Tachynopoulou, Varvara ; Skoumi, Dimitra ; Tsompanakou, Aliki ; Stavropoulos-Giokas, Aikaterini ; Vadikolia, Chrysanthi ; Anagnostopoulos, Achilles ; Paterakis, Georgios</creatorcontrib><description>Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measurement in CLL samples. Samples from 61 CLL patients and 44 normal subjects were analyzed using a commercial ZAP-70 monoclonal antibody (1E7.2 clone) conjugated with phycoerythrin (PE) and Alexa 488 fluorochromes. Modifications of the published methods led to the structure of a simplified in-house method of ZAP-70 measurement. A three-color approach was used with CD19, CD3 gating comparing with the isotype control provided by the same manufacturer. The cutoff levels for ZAP-70 positivity were defined from a receiver operator characteristic curve in relation to the IgV(H) mutational status and from the ln normalized mean value +2 SD of normal controls. Using the 20% cutoff value for ZAP-70 positivity in CLL patients defined by the literature, ZAP-PE had a sensitivity of 55% and a specificity of 98% in predicting the IgV(H) mutational status, whereas the corresponding values for ZAP-Alexa were 55% and 84%, respectively. Using the 7% cutoff value for CD38 positivity, the sensitivity was 55%, whereas the specificity was 76%. ZAP-70-positive patients showed a shorter time to disease progression in comparison with ZAP-70-negative patients (p < 0.001). In conclusion, the 100% specific prediction of mutational status is accompanied by reduced sensitivity, thus limiting ZAP-70's applicability either as a single marker or combined with CD38 for the assessment of the mutational status of CLL.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-006-0159-4</identifier><identifier>PMID: 16871389</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>ADP-ribosyl Cyclase 1 - analysis ; Adult ; Aged ; Antigens, CD19 ; Biomarkers - analysis ; Case-Control Studies ; CD3 Complex ; Disease Progression ; Feasibility Studies ; Female ; Flow cytometry ; Flow Cytometry - methods ; Flow Cytometry - standards ; Humans ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell - enzymology ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Lymphocytes ; Male ; Methods ; Middle Aged ; Prognosis ; Reference Standards ; ROC Curve ; Survival Analysis ; ZAP-70 Protein-Tyrosine Kinase - analysis</subject><ispartof>Annals of hematology, 2006-11, Vol.85 (11), p.795-805</ispartof><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-1ad7d885d0926ca3136c614db1a1e9f0e2136a1dab695f435a2a85fbd6e150fa3</citedby><cites>FETCH-LOGICAL-c421t-1ad7d885d0926ca3136c614db1a1e9f0e2136a1dab695f435a2a85fbd6e150fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16871389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Passam, Freda</creatorcontrib><creatorcontrib>Tachynopoulou, Varvara</creatorcontrib><creatorcontrib>Skoumi, Dimitra</creatorcontrib><creatorcontrib>Tsompanakou, Aliki</creatorcontrib><creatorcontrib>Stavropoulos-Giokas, Aikaterini</creatorcontrib><creatorcontrib>Vadikolia, Chrysanthi</creatorcontrib><creatorcontrib>Anagnostopoulos, Achilles</creatorcontrib><creatorcontrib>Paterakis, Georgios</creatorcontrib><title>Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measurement in CLL samples. Samples from 61 CLL patients and 44 normal subjects were analyzed using a commercial ZAP-70 monoclonal antibody (1E7.2 clone) conjugated with phycoerythrin (PE) and Alexa 488 fluorochromes. Modifications of the published methods led to the structure of a simplified in-house method of ZAP-70 measurement. A three-color approach was used with CD19, CD3 gating comparing with the isotype control provided by the same manufacturer. The cutoff levels for ZAP-70 positivity were defined from a receiver operator characteristic curve in relation to the IgV(H) mutational status and from the ln normalized mean value +2 SD of normal controls. Using the 20% cutoff value for ZAP-70 positivity in CLL patients defined by the literature, ZAP-PE had a sensitivity of 55% and a specificity of 98% in predicting the IgV(H) mutational status, whereas the corresponding values for ZAP-Alexa were 55% and 84%, respectively. Using the 7% cutoff value for CD38 positivity, the sensitivity was 55%, whereas the specificity was 76%. ZAP-70-positive patients showed a shorter time to disease progression in comparison with ZAP-70-negative patients (p < 0.001). In conclusion, the 100% specific prediction of mutational status is accompanied by reduced sensitivity, thus limiting ZAP-70's applicability either as a single marker or combined with CD38 for the assessment of the mutational status of CLL.</description><subject>ADP-ribosyl Cyclase 1 - analysis</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens, CD19</subject><subject>Biomarkers - analysis</subject><subject>Case-Control Studies</subject><subject>CD3 Complex</subject><subject>Disease Progression</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Flow Cytometry - methods</subject><subject>Flow Cytometry - standards</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - enzymology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Reference Standards</subject><subject>ROC Curve</subject><subject>Survival Analysis</subject><subject>ZAP-70 Protein-Tyrosine Kinase - analysis</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkUGL1TAUhYMoznP0B7iR4MJdNDdp09TdY3BUGNCFbtyENL2dZkybZ9Ii_Tn-U1PeA8FsEs4995zAR8hL4G-B8-Zd5lw0DeNcMQ51y6pH5ACVFIzXunpMDryVLavLuSLPcn7gHISuxFNyBUo3IHV7IH9u0Wbf-eCXjcaB2pnuQtioPZ2Cd7YLSCdcxtjv4x_Hr6zhRbB5TTjhvFA_UzemOHtHwzadxui2ZX_j-hMnb_f5MiJNcV38jHQI8TctllhC00YzLkW-f0-Pl5YY4n2pDXt_itaNz8mTwYaMLy73Nfl---HbzSd29-Xj55vjHXOVgIWB7Zte67rnrVDOSpDKKaj6DixgO3AURbHQ20619VDJ2gqr66HrFULNByuvyZtzbqn9tWJezOSzwxDsjHHNRmldKQ2iGF__Z3yIa5rL34wC2dYcWllMcDa5FHNOOJhT8pNNmwFudnjmDM8UeGaHZ6qy8-oSvHYT9v82LrTkX5Kbl9M</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Passam, Freda</creator><creator>Tachynopoulou, Varvara</creator><creator>Skoumi, Dimitra</creator><creator>Tsompanakou, Aliki</creator><creator>Stavropoulos-Giokas, Aikaterini</creator><creator>Vadikolia, Chrysanthi</creator><creator>Anagnostopoulos, Achilles</creator><creator>Paterakis, Georgios</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach</title><author>Passam, Freda ; Tachynopoulou, Varvara ; Skoumi, Dimitra ; Tsompanakou, Aliki ; Stavropoulos-Giokas, Aikaterini ; Vadikolia, Chrysanthi ; Anagnostopoulos, Achilles ; Paterakis, Georgios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-1ad7d885d0926ca3136c614db1a1e9f0e2136a1dab695f435a2a85fbd6e150fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>ADP-ribosyl Cyclase 1 - analysis</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens, CD19</topic><topic>Biomarkers - analysis</topic><topic>Case-Control Studies</topic><topic>CD3 Complex</topic><topic>Disease Progression</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Flow Cytometry - methods</topic><topic>Flow Cytometry - standards</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - enzymology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Reference Standards</topic><topic>ROC Curve</topic><topic>Survival Analysis</topic><topic>ZAP-70 Protein-Tyrosine Kinase - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Passam, Freda</creatorcontrib><creatorcontrib>Tachynopoulou, Varvara</creatorcontrib><creatorcontrib>Skoumi, Dimitra</creatorcontrib><creatorcontrib>Tsompanakou, Aliki</creatorcontrib><creatorcontrib>Stavropoulos-Giokas, Aikaterini</creatorcontrib><creatorcontrib>Vadikolia, Chrysanthi</creatorcontrib><creatorcontrib>Anagnostopoulos, Achilles</creatorcontrib><creatorcontrib>Paterakis, Georgios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Passam, Freda</au><au>Tachynopoulou, Varvara</au><au>Skoumi, Dimitra</au><au>Tsompanakou, Aliki</au><au>Stavropoulos-Giokas, Aikaterini</au><au>Vadikolia, Chrysanthi</au><au>Anagnostopoulos, Achilles</au><au>Paterakis, Georgios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach</atitle><jtitle>Annals of hematology</jtitle><addtitle>Ann Hematol</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>85</volume><issue>11</issue><spage>795</spage><epage>805</epage><pages>795-805</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Zeta-associated protein 70 (ZAP-70), determined by flow cytometry, has been advocated a surrogate marker of immunoglobulin (Ig)V(H) unmutated status in B chronic lymphocytic leukemia (CLL). The aim of the current study was to test the applicability of an easy flow cytometry protocol for ZAP-70 measurement in CLL samples. Samples from 61 CLL patients and 44 normal subjects were analyzed using a commercial ZAP-70 monoclonal antibody (1E7.2 clone) conjugated with phycoerythrin (PE) and Alexa 488 fluorochromes. Modifications of the published methods led to the structure of a simplified in-house method of ZAP-70 measurement. A three-color approach was used with CD19, CD3 gating comparing with the isotype control provided by the same manufacturer. The cutoff levels for ZAP-70 positivity were defined from a receiver operator characteristic curve in relation to the IgV(H) mutational status and from the ln normalized mean value +2 SD of normal controls. Using the 20% cutoff value for ZAP-70 positivity in CLL patients defined by the literature, ZAP-PE had a sensitivity of 55% and a specificity of 98% in predicting the IgV(H) mutational status, whereas the corresponding values for ZAP-Alexa were 55% and 84%, respectively. Using the 7% cutoff value for CD38 positivity, the sensitivity was 55%, whereas the specificity was 76%. ZAP-70-positive patients showed a shorter time to disease progression in comparison with ZAP-70-negative patients (p < 0.001). In conclusion, the 100% specific prediction of mutational status is accompanied by reduced sensitivity, thus limiting ZAP-70's applicability either as a single marker or combined with CD38 for the assessment of the mutational status of CLL.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>16871389</pmid><doi>10.1007/s00277-006-0159-4</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-5555 |
ispartof | Annals of hematology, 2006-11, Vol.85 (11), p.795-805 |
issn | 0939-5555 1432-0584 |
language | eng |
recordid | cdi_proquest_miscellaneous_68846812 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | ADP-ribosyl Cyclase 1 - analysis Adult Aged Antigens, CD19 Biomarkers - analysis Case-Control Studies CD3 Complex Disease Progression Feasibility Studies Female Flow cytometry Flow Cytometry - methods Flow Cytometry - standards Humans Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - enzymology Leukemia, Lymphocytic, Chronic, B-Cell - mortality Lymphocytes Male Methods Middle Aged Prognosis Reference Standards ROC Curve Survival Analysis ZAP-70 Protein-Tyrosine Kinase - analysis |
title | Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A19%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20an%20easily%20applicable%20method%20of%20ZAP-70%20measurement%20in%20chronic%20lymphocytic%20leukemia%20in%20the%20routine%20flow%20cytometry%20setting:%20A%20methodological%20approach&rft.jtitle=Annals%20of%20hematology&rft.au=Passam,%20Freda&rft.date=2006-11-01&rft.volume=85&rft.issue=11&rft.spage=795&rft.epage=805&rft.pages=795-805&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-006-0159-4&rft_dat=%3Cproquest_cross%3E68846812%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=613950193&rft_id=info:pmid/16871389&rfr_iscdi=true |